SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Grith P. Eng, Klaus Bendtzen, Henning Bliddal, Michael Stoltenberg, Marcin Szkudlarek, Viktoria Fana, Hanne M. Lindegaard, Emina Omerovic, Pil Højgaard, Elmo K. Jensen, Pierre N. Bouchelouche, Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study, Arthritis, 2015, 2015, 1

    CrossRef

  2. 2
    Tomonori Kobayakawa, Toshihisa Kojima, Nobunori Takahashi, Masatoshi Hayashi, Yuichiro Yabe, Atsushi Kaneko, Tomone Shioura, Kiwamu Saito, Yuji Hirano, Yasuhide Kanayama, Hiroyuki Miyake, Nobuyuki Asai, Koji Funahashi, Shinya Hirabara, Masahiro Hanabayashi, Shuji Asai, Naoki Ishiguro, Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate, Modern Rheumatology, 2015, 25, 2, 251

    CrossRef

  3. 3
    Denis Jullien, Jörg C Prinz, Frank O Nestle, Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes, Journal of Investigative Dermatology, 2015, 135, 1, 31

    CrossRef

  4. 4
    Ibon Eguíluz-Gracia, Teresa Robledo-Echarren, Ricardo Suárez-Fernández, Montserrat Fernández-Rivas, Silvia Sánchez-Ramón, Omalizumab for the treatment of atopic dermatitis, Clinical Investigation, 2015, 5, 2, 121

    CrossRef

  5. You have free access to this content5
    Niels Vande Casteele, Ann Gils, Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice, The Journal of Clinical Pharmacology, 2015, 55, S3
  6. 6
    Eun Wha Choi, Tae Won Yun, Ji Woo Song, Minjae Lee, Jehoon Yang, Kyu-Sil Choi, Preventive effects of CTLA4Ig-overexpressing adipose tissue–derived mesenchymal stromal cells in rheumatoid arthritis, Cytotherapy, 2015, 17, 3, 271

    CrossRef

  7. 7
    Ariana Montes, Eva Perez-Pampin, Federico Navarro-Sarabia, Virginia Moreira, Arturo Rodríguez de la Serna, Berta Magallares, Yiannis Vasilopoulos, Theologia Sarafidou, Antonio Fernández-Nebro, María del Carmen Ordóñez, Javier Narváez, Juan D Cañete, Ana Marquez, Dora Pascual-Salcedo, Beatriz Joven, Patricia Carreira, Manuel J Moreno-Ramos, Rafael Caliz, Miguel Angel Ferrer, Rosa Garcia-Portales, Francisco J Blanco, Cesar Magro, Enrique Raya, Lara Valor, Juan J Alegre-Sancho, Alejandro Balsa, Javier Martin, Darren Plant, John Isaacs, Ann W Morgan, Anne Barton, Anthony G Wilson, Juan J Gómez-Reino, Antonio Gonzalez, Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study, Arthritis Research & Therapy, 2015, 17, 1

    CrossRef

  8. 8
    Konstantinos Papamichael, Ann Gils, Paul Rutgeerts, Barrett G. Levesque, Séverine Vermeire, William J. Sandborn, Niels Vande Casteele, Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD, Inflammatory Bowel Diseases, 2015, 21, 1, 182

    CrossRef

  9. 9
    D.-Y. Chen, Y.-M. Chen, W.-C. Tsai, J.-C. Tseng, Y.-H. Chen, C.-W. Hsieh, W.-T. Hung, J.-L. Lan, Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis, Annals of the Rheumatic Diseases, 2015, 74, 3, e16

    CrossRef

  10. 10
    Karien Bloem, Astrid van Leeuwen, Gerrit Verbeek, Michael T. Nurmohamed, Gerrit Jan Wolbink, Desiree van der Kleij, Theo Rispens, Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients, Journal of Immunological Methods, 2015, 418, 29

    CrossRef

  11. 11
    K. A. van Schie, M. H. Hart, E. R. de Groot, S. Kruithof, L. A. Aarden, G. J. Wolbink, T. Rispens, The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region, Annals of the Rheumatic Diseases, 2015, 74, 1, 311

    CrossRef

  12. 12
    Maria A.V. Willrich, David L. Murray, Melissa R. Snyder, Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases, Translational Research, 2015, 165, 2, 270

    CrossRef

  13. 13
    S. Garces, M. Antunes, E. Benito-Garcia, J. C. da Silva, L. Aarden, J. Demengeot, A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies, Annals of the Rheumatic Diseases, 2014, 73, 6, 1138

    CrossRef

  14. 14
    J. M. Sailstad, L. Amaravadi, A. Clements-Egan, B. Gorovits, H. A. Myler, R. C. Pillutla, S. Pursuhothama, M. Putman, M. K. Rose, K. Sonehara, L. Tang, J. T. Wustner, A White Paper—Consensus and Recommendations of a Global Harmonization Team on Assessing the Impact of Immunogenicity on Pharmacokinetic Measurements, The AAPS Journal, 2014, 16, 3, 488

    CrossRef

  15. 15
    Hong Yang, Arthur Kavanaugh, Adverse effects of golimumab in the treatment of rheumatologic diseases, Expert Opinion on Drug Safety, 2014, 13, 1, 103

    CrossRef

  16. 16
    Madeline Therese Frederiksen, Mark Andrew Ainsworth, Jørn Brynskov, Ole Østergaard Thomsen, Klaus Bendtzen, Casper Steenholdt, Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD, Inflammatory Bowel Diseases, 2014, 20, 10, 1714

    CrossRef

  17. 17
    David Ternant, Zahir Berkane, Laurence Picon, Valérie Gouilleux-Gruart, Jean-Frédéric Colombel, Matthieu Allez, Edouard Louis, Gilles Paintaud, Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease, Clinical Pharmacokinetics, 2014,

    CrossRef

  18. 18
    Ethan C. Levin, Rishu Gupta, Gabrielle Brown, Mona Malakouti, John Koo, Biologic fatigue in psoriasis, Journal of Dermatological Treatment, 2014, 25, 1, 78

    CrossRef

  19. 19
    Silvano Sozzani, Maria P. Abbracchio, Vito Annese, Silvio Danese, Ornella De Pità, Giovambattista De Sarro, Sabatino Maione, Ignazio Olivieri, Aurora Parodi, Piercarlo Sarzi-Puttini, Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review, Autoimmunity, 2014, 47, 5, 287

    CrossRef

  20. 20
    Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov, Ole \[emptyv] Thomsen, Mark A Ainsworth, Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial, The American Journal of Gastroenterology, 2014, 109, 7, 1055

    CrossRef

  21. 21
    Reena Khanna, Brian G. Feagan, Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD, Current Treatment Options in Gastroenterology, 2014, 12, 1, 76

    CrossRef

  22. 22
    C. Steenholdt, J. Brynskov, O. O. Thomsen, L. K. Munck, J. Fallingborg, L. A. Christensen, G. Pedersen, J. Kjeldsen, B. A. Jacobsen, A. S. Oxholm, J. Kjellberg, K. Bendtzen, M. A. Ainsworth, Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial, Gut, 2014, 63, 6, 919

    CrossRef

  23. 23
    Cecilia Beatrice Chighizola, Ennio Giulio Favalli, Pier Luigi Meroni, Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases, Clinical Reviews in Allergy & Immunology, 2014, 47, 1, 6

    CrossRef

  24. 24
    Shomron Ben-Horin, Uri Kopylov, Yehuda Chowers, Optimizing anti-TNF treatments in inflammatory bowel disease, Autoimmunity Reviews, 2014, 13, 1, 24

    CrossRef

  25. 25
    Gianfranco Pasut, Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol, BioDrugs, 2014, 28, S1, 15

    CrossRef

  26. 26
    David Ternant, Emilie Ducourau, Aleth Perdriger, Anca Corondan, Benoît Le Goff, Valérie Devauchelle-Pensec, Elisabeth Solau-Gervais, Hervé Watier, Philippe Goupille, Gilles Paintaud, Denis Mulleman, Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis, British Journal of Clinical Pharmacology, 2014, 78, 1
  27. 27
    Shomron Ben-Horin, Yehuda Chowers, Tailoring anti-TNF therapy in IBD: drug levels and disease activity, Nature Reviews Gastroenterology & Hepatology, 2014, 11, 4, 243

    CrossRef

  28. 28
    Tzeyu L. Michaud, Young Hee Rho, Tatyana Shamliyan, Karen M. Kuntz, Hyon K. Choi, The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials, The American Journal of Medicine, 2014, 127, 12, 1208

    CrossRef

  29. 29
    Mauro Keiserman, Catalin Codreanu, Rohini Handa, Daniel Xibillé-Friedmann, Eduardo Mysler, Francisco Briceño, Servet Akar, The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences, Expert Review of Clinical Immunology, 2014, 10, 8, 1049

    CrossRef

  30. 30
    M. Jani, A. Barton, R. B. Warren, C. E. M. Griffiths, H. Chinoy, The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases, Rheumatology, 2014, 53, 2, 213

    CrossRef

  31. 31
    Elizabeth A. Kessler, Mara L. Becker, Therapeutic advancements in juvenile idiopathic arthritis, Best Practice & Research Clinical Rheumatology, 2014, 28, 2, 293

    CrossRef

  32. 32
    Misato Hashizume, Seng-Lai Tan, Junichi Takano, Kazunori Ohsawa, Ikuo Hasada, Akira Hanasaki, Ichiro Ito, Masahiko Mihara, Keiichiro Nishida, Tocilizumab, A Humanized Anti-IL-6R Antibody, as an Emerging Therapeutic Option for Rheumatoid Arthritis: Molecular and Cellular Mechanistic Insights, International Reviews of Immunology, 2014, 140924103246004

    CrossRef

  33. 33
    Mahmoud H Mosli, William J Sandborn, Richard B Kim, Reena Khanna, Bandar Al-Judaibi, Brian G Feagan, Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease, The American Journal of Gastroenterology, 2014, 109, 7, 994

    CrossRef

  34. 34
    Adriana Rivero Marcotegui, Rosario Ibañez Bosch, Andrés Zuñiga Vera, Antonio Arín Letamendia, María Jesús Burusco Paternain, Utilidad clínica de la cuantificación de infliximab y anticuerpos antiquiméricos humanos, Revista del Laboratorio Clínico, 2014, 7, 2, 68

    CrossRef

  35. 35
    Ethan Levin, John Koo, Moderate to Severe Psoriasis, Fourth Edition, 2014,

    CrossRef

  36. 36
    D. H. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanovic, M. Abello-Banfi, S. Gutierrez-Urena, L. Morales-Olazabal, M. Tee, R. Jimenez, O. Zamani, S. J. Lee, H. Kim, W. Park, U. Muller-Ladner, A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study, Annals of the Rheumatic Diseases, 2013, 72, 10, 1613

    CrossRef

  37. 37
    Masaru Takeuchi, A systematic review of biologics for the treatment of noninfectious uveitis, Immunotherapy, 2013, 5, 1, 91

    CrossRef

  38. 38
    Martin F. Bachmann, Piers Whitehead, Active immunotherapy for chronic diseases, Vaccine, 2013, 31, 14, 1777

    CrossRef

  39. 39
    Paul Chamberlain, Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations, Bioanalysis, 2013, 5, 5, 561

    CrossRef

  40. 40
    Raja K. Sivamani, Heidi Goodarzi, Miki Shirakawa Garcia, Siba P. Raychaudhuri, Lisa N. Wehrli, Yoko Ono, Emanual Maverakis, Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring, Clinical Reviews in Allergy & Immunology, 2013, 44, 2, 121

    CrossRef

  41. 41
    Jean G. Sathish, Swaminathan Sethu, Marie-Christine Bielsky, Lolke de Haan, Neil S. French, Karthik Govindappa, James Green, Christopher E. M. Griffiths, Stephen Holgate, David Jones, Ian Kimber, Jonathan Moggs, Dean J. Naisbitt, Munir Pirmohamed, Gabriele Reichmann, Jennifer Sims, Meena Subramanyam, Marque D. Todd, Jan Willem Van Der Laan, Richard J. Weaver, B. Kevin Park, Challenges and approaches for the development of safer immunomodulatory biologics, Nature Reviews Drug Discovery, 2013, 12, 4, 306

    CrossRef

  42. 42
    Casper Steenholdt, Mark A. Ainsworth, Michael Tovey, Tobias W. Klausen, Ole Ø. Thomsen, Jørn Brynskov, Klaus Bendtzen, Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohnʼs Disease, Therapeutic Drug Monitoring, 2013, 35, 4, 530

    CrossRef

  43. 43
    Lara Valor, Inmaculada de la Torre, Comprender el concepto de inmunogenicidad, Reumatología Clínica, 2013, 9, 1, 1

    CrossRef

  44. 44
    Theo Rispens, Margreet H. Hart, Pleuni Ooijevaar-de Heer, Astrid van Leeuwen, Anke Vennegoor, Joep Killestein, Gerrit-Jan Wolbink, Desiree van der Kleij, Drug interference in immunogenicity assays depends on valency, Journal of Pharmaceutical and Biomedical Analysis, 2013, 85, 179

    CrossRef

  45. 45
    Alexander Eser, Christian Primas, Walter Reinisch, Drug monitoring of biologics in inflammatory bowel disease, Current Opinion in Gastroenterology, 2013, 29, 4, 391

    CrossRef

  46. 46
    C. Nhim, S. Delluc, F. Halgand, L. Chaisemartin, R. J. Weaver, N. Claude, D. Joseph, B. Maillère, M. Pallardy, Identification and frequency of circulating CD4+ T lymphocytes specific to Benzylpenicillin in healthy donors, Allergy, 2013, 68, 7
  47. 47
    J.M. Carrascosa, Immunogenicity in Biologic Therapy: Implications for Dermatology, Actas Dermo-Sifiliográficas (English Edition), 2013, 104, 6, 471

    CrossRef

  48. 48
    Pauline A. van Schouwenburg, Theo Rispens, Gerrit Jan Wolbink, Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis, Nature Reviews Rheumatology, 2013, 9, 3, 164

    CrossRef

  49. 49
    Clara De Simone, Paolo Amerio, Giuseppe Amoruso, Federico Bardazzi, Anna Campanati, Andrea Conti, Paolo Gisondi, Giulio Gualdi, Claudio Guarneri, Luca Leoni, Francesco Loconsole, Annamaria Mazzotta, Maria Letizia Musumeci, Stefano Piaserico, Concetta Potenza, Francesca Prestinari, Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?, Expert Opinion on Biological Therapy, 2013, 13, 12, 1673

    CrossRef

  50. 50
    J.M. Carrascosa, Inmunogenicidad en terapia biológica. Implicaciones en Dermatología, Actas Dermo-Sifiliográficas, 2013, 104, 6, 471

    CrossRef

  51. 51
    P. A. van Schouwenburg, C. L. Krieckaert, T. Rispens, L. Aarden, G. J. Wolbink, D. Wouters, Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation, Annals of the Rheumatic Diseases, 2013, 72, 10, 1680

    CrossRef

  52. 52
    Maarten L. Zandvliet, Jine S. van Bezooijen, Mariska A. Bos, Errol P. Prens, Martijn van Doorn, Ilona Bijen, Marco W. J. Schreurs, Vincent H. J. van der Velden, Birgit C. P. Koch, Teun van Gelder, Monitoring Antigen-Specific Biologics, Therapeutic Drug Monitoring, 2013, 1

    CrossRef

  53. 53
    Shui-Long Wang, Scott Hauenstein, Linda Ohrmund, Reshma Shringarpure, Jared Salbato, Rukmini Reddy, Kevin McCowen, Shawn Shah, Steven Lockton, Emil Chuang, Sharat Singh, Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay, Journal of Pharmaceutical and Biomedical Analysis, 2013, 78-79, 39

    CrossRef

  54. You have free access to this content54
    R. Khanna, B. D. Sattin, W. Afif, E. I. Benchimol, E.-J. Bernard, A. Bitton, B. Bressler, R. N. Fedorak, S. Ghosh, G. R. Greenberg, J. K. Marshall, R. Panaccione, E. G. Seidman, M. S. Silverberg, A. H. Steinhart, R. Sy, G. Van Assche, T. D. Walters, W. J. Sandborn, B. G. Feagan, Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2013, 38, 5
  55. 55
    M. Schiff, Subcutaneous abatacept for the treatment of rheumatoid arthritis, Rheumatology, 2013, 52, 6, 986

    CrossRef

  56. You have free access to this content56
    Bart J. F. Bemt, Alfons A. Broeder, Gert-Jan Wolbink, Aatke Maas, Yechiel A. Hekster, Piet L. C. M. Riel, H. Bart Benraad, Frank H. J. Hoogen, The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis, British Journal of Clinical Pharmacology, 2013, 76, 6
  57. 57
    S. B. Krintel, V. P. Grunert, M. L. Hetland, J. S. Johansen, M. Rothfuss, G. Palermo, L. Essioux, U. Klause, The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure, Rheumatology, 2013, 52, 7, 1245

    CrossRef

  58. 58
    S. Garces, J. Demengeot, E. Benito-Garcia, The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis, Annals of the Rheumatic Diseases, 2013, 72, 12, 1947

    CrossRef

  59. 59
    Chamaida Plasencia, Dora Pascual-Salcedo, Sara García-Carazo, Leticia Lojo, Laura Nuño, Alejandro Villalba, Diana Peiteado, Florencia Arribas, Jesus Díez, Maria Teresa López-Casla, Emilio Martín-Mola, Alejandro Balsa, The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients, Arthritis Research & Therapy, 2013, 15, 4, R79

    CrossRef

  60. 60
    Lara Valor, Inmaculada de la Torre, Understanding the Immunogenicity Concept, Reumatología Clínica (English Edition), 2013, 9, 1, 1

    CrossRef

  61. 61
    Karen D. Price, Gautham K. Rao, Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics, 2013,

    CrossRef

  62. 62
    Casper Steenholdt, Morten Svenson, Klaus Bendtzen, Ole Østergaard Thomsen, Jørn Brynskov, Mark Andrew Ainsworth, Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease, Journal of Crohn's and Colitis, 2012, 6, 1, 108

    CrossRef

  63. 63
    Klaus Bendtzen, Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine, Immunotherapy, 2012, 4, 11, 1167

    CrossRef

  64. 64
    Theo Rispens, Henk de Vrieze, Els de Groot, Diana Wouters, Steven Stapel, Gerrit J. Wolbink, Lucien A. Aarden, Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing, Journal of Immunological Methods, 2012, 375, 1-2, 93

    CrossRef

  65. 65
    D. Jullien, Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis, Annales de Dermatologie et de Vénéréologie, 2012, 139, S58

    CrossRef

  66. 66
    Gilles Paintaud, Marine Diviné, Philippe Lechat, Anticorps monoclonaux à usage thérapeutique : spécificités du développement clinique, évaluation par les agences, suivi de la tolérance à long terme, Thérapie, 2012, 67, 4, 319

    CrossRef

  67. 67
    Casper Steenholdt, Magid Al-khalaf, Jørn Brynskov, Klaus Bendtzen, Ole Ø. Thomsen, Mark A. Ainsworth, Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease, Inflammatory Bowel Diseases, 2012, 18, 12
  68. 68
    Shui-Long Wang, Linda Ohrmund, Scott Hauenstein, Jared Salbato, Rukmini Reddy, Patrick Monk, Steven Lockton, Nicholas Ling, Sharat Singh, Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum, Journal of Immunological Methods, 2012, 382, 1-2, 177

    CrossRef

  69. 69
    R. A. Farrell, M. Marta, A. J. Gaeguta, V. Souslova, G. Giovannoni, P. I. Creeke, Development of resistance to biologic therapies with reference to IFN- , Rheumatology, 2012, 51, 4, 590

    CrossRef

  70. 70
    Denis Mulleman, Émilie Ducourau, Gilles Paintaud, David Ternant, Hervé Watier, Philippe Goupille, Doit-on mesurer les concentrations sériques d’anti-TNF-α et/ou d’anticorps anti-médicament au cours de la polyarthrite rhumatoïde ?, Revue du Rhumatisme, 2012, 79, 2, 97

    CrossRef

  71. 71
    Charlotte Krieckaert, Theo Rispens, Gertjan Wolbink, Immunogenicity of biological therapeutics, Current Opinion in Rheumatology, 2012, 24, 3, 306

    CrossRef

  72. 72
    Michael G Tovey, Christophe Lallemand, Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals, Bioanalysis, 2012, 4, 17, 2179

    CrossRef

  73. 73
    Erna Harboe, Jan Damås, Roald Omdal, Stig Frøland, Haakon Sjursen, Infeksjonsrisiko ved bruk av selektivt immunmodulerende midler mot revmatoid artritt, Tidsskrift for Den norske legeforening, 2012, 132, 16, 1867

    CrossRef

  74. 74
    Misato Hashizume, Hiroto Yoshida, Keisuke Tanaka, Miho Suzuki, Isao Matsumoto, Takayuki Sumida, Masahiko Mihara, Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model, Arthritis Research & Therapy, 2012, 14, 2, R96

    CrossRef

  75. 75
    C. Steenholdt, J. Brynskov, K. Bendtzen, Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD, Alimentary Pharmacology & Therapeutics, 2012, 36, 5
  76. 76
    Gilles Paintaud, Marine Diviné, Philippe Lechat, Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety, Thérapie, 2012, 67, 4, 329

    CrossRef

  77. 77
    Rong Deng, Feng Jin, Saileta Prabhu, Suhasini Iyer, Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?, Expert Opinion on Drug Metabolism & Toxicology, 2012, 8, 2, 141

    CrossRef

  78. 78
    Themistocles Dassopoulos, Charles A. Sninsky, Optimizing Immunomodulators and Anti-TNF Agents in the Therapy of Crohn Disease, Gastroenterology Clinics of North America, 2012, 41, 2, 393

    CrossRef

  79. 79
    BC Visser, IH Brinkman, Mart AFJ van de Laar, Personalized medicine in rheumatoid arthritis: rationale and clinical evidence, Clinical Investigation, 2012, 2, 8, 797

    CrossRef

  80. 80
    Denis Mulleman, Emilie Ducourau, Gilles Paintaud, David Ternant, Hervé Watier, Philippe Goupille, Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?, Joint Bone Spine, 2012, 79, 2, 109

    CrossRef

  81. 81
    Casper Steenholdt, Magid Al-Khalaf, Mark A. Ainsworth, Jørn Brynskov, Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31, Journal of Crohn's and Colitis, 2012, 6, 3, 358

    CrossRef

  82. 82
    Alan Reynolds, Andrew S Koenig, Eustratios Bananis, Amitabh Singh, When is switching warranted among biologic therapies in rheumatoid arthritis?, Expert Review of Pharmacoeconomics & Outcomes Research, 2012, 12, 3, 319

    CrossRef

  83. 83
    Enrico Maggi, Alessandra Vultaggio, Andrea Matucci, Acute infusion reactions induced by monoclonal antibody therapy, Expert Review of Clinical Immunology, 2011, 7, 1, 55

    CrossRef

  84. 84
    Nishanthi Thalayasingam, John D. Isaacs, Anti-TNF therapy, Best Practice & Research Clinical Rheumatology, 2011, 25, 4, 549

    CrossRef

  85. 85
    Emilie Ducourau, Denis Mulleman, Gilles Paintaud, Delphine Miow Lin, Francine Lauféron, David Ternant, Hervé Watier, Philippe Goupille, Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases, Arthritis Research & Therapy, 2011, 13, 3, R105

    CrossRef

  86. 86
    Sylvie Fabre, Approches pharmacologiques en immuno-rhumatologie, Thérapie, 2011, 66, 5, 397

    CrossRef

  87. 87
    Henit Yanai, Stephen B Hanauer, Assessing Response and Loss of Response to Biological Therapies in IBD, The American Journal of Gastroenterology, 2011, 106, 4, 685

    CrossRef

  88. 88
    Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov, Ole Østergaard Thomsen, Mark Andrew Ainsworth, Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease, Scandinavian Journal of Gastroenterology, 2011, 46, 3, 310

    CrossRef

  89. 89
    Denis Mulleman, Francine Lauféron, Daniel Wendling, David Ternant, Emilie Ducourau, Gilles Paintaud, Philippe Goupille, Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study, Arthritis Research & Therapy, 2011, 13, 3, R82

    CrossRef

  90. 90
    D. Pascual-Salcedo, C. Plasencia, S. Ramiro, L. Nuno, G. Bonilla, D. Nagore, A. Ruiz del Agua, A. Martinez, L. Aarden, E. Martin-Mola, A. Balsa, Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis, Rheumatology, 2011, 50, 8, 1445

    CrossRef

  91. 91
    Klaus Bendtzen, Is there a need for immunopharmacologic guidance of anti–tumor necrosis factor therapies?, Arthritis & Rheumatism, 2011, 63, 4
  92. 92
    Liisa M. Virkki, Heikki Valleala, Yuya Takakubo, Jorma Vuotila, Heikki Relas, Riitta Komulainen, Riitta Koivuniemi, Urpo Yli-Kerttula, Markku Mali, Susanna Sihvonen, Maija-Liisa Krogerus, Eero Jukka, Satu Nyrhinen, Yrjö T. Konttinen, Dan C. Nordström, Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN), Clinical Rheumatology, 2011, 30, 11, 1447

    CrossRef

  93. 93
    Christophe Lallemand, Nadia Kavrochorianou, Casper Steenholdt, Klaus Bendtzen, Mark A. Ainsworth, Jean-Francois Meritet, Brigitte Blanchard, Pierre Lebon, Peter Taylor, Peter Charles, Saba Alzabin, Michael G. Tovey, Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists, Journal of Immunological Methods, 2011, 373, 1-2, 229

    CrossRef

  94. You have free access to this content94
    S. Ben-Horin, Y. Chowers, Review article: loss of response to anti-TNF treatments in Crohn’s disease, Alimentary Pharmacology & Therapeutics, 2011, 33, 9
  95. 95
    C. Steenholdt, M. Svenson, K. Bendtzen, O. Ø. Thomsen, J. Brynskov, M. A. Ainsworth, Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2011, 34, 1
  96. 96
    Akira Sagawa, The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab, Modern Rheumatology, 2011, 21, 4, 352

    CrossRef

  97. 97
    Akira Sagawa, The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab, Modern Rheumatology, 2011, 21, 4, 352

    CrossRef

  98. 98
    Jean-Camille Méric, Denis Mulleman, Emilie Ducourau, Francine Lauféron, Delphine Chu Miow Lin, Hervé Watier, Philippe Goupille, Gilles Paintaud, Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study, Therapeutic Drug Monitoring, 2011, 33, 4, 411

    CrossRef

  99. 99
    Devesh Mewar, Anthony G Wilson, Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors, British Journal of Pharmacology, 2011, 162, 4
  100. 100
    L. A. Korswagen, G. M. Bartelds, C. L. M. Krieckaert, F. Turkstra, M. T. Nurmohamed, D. van Schaardenburg, C. A. Wijbrandts, P. P. Tak, W. F. Lems, B. A. C. Dijkmans, R. M. van Vugt, G. J. Wolbink, Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study, Arthritis & Rheumatism, 2011, 63, 4
  101. 101
    Juan Jin, Yan Chang, Wei Wei, Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis, Acta Pharmacologica Sinica, 2010, 31, 9, 1133

    CrossRef

  102. 102
    Ron J. Keizer, Alwin D.R. Huitema, Jan H.M. Schellens, Jos H. Beijnen, Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies, Clinical Pharmacokinetics, 2010, 49, 8, 493

    CrossRef

  103. 103
    Waqqas Afif, Edward V Loftus, William A Faubion, Sunanda V Kane, David H Bruining, Karen A Hanson, William J Sandborn, Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease, The American Journal of Gastroenterology, 2010, 105, 5, 1133

    CrossRef

  104. 104
    A. A. den Broeder, A. van der Maas, B. J. F. van den Bemt, Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA, Rheumatology, 2010, 49, 10, 1801

    CrossRef

  105. 105
    M. Blom, W. Kievit, H. H. Kuper, T. L. Jansen, H. Visser, A. A. den Broeder, H. L. M. Brus, M. A. F. J. van de Laar, P. L. C. M. van Riel, Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice, Arthritis Care & Research, 2010, 62, 9
  106. 106
    Nádia Emi Aikawa, Jozélio Freire de Carvalho, Clovis Artur Almeida Silva, Eloísa Bonfá, Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases, Clinical Reviews in Allergy & Immunology, 2010, 38, 2-3, 82

    CrossRef

  107. 107
    Utako KANEKO, Takayuki KISHI, Masako KIKUCHI, Ryoki HARA, Toshihiko SHINOKI, Takako MIYAMAE, Tomoyuki IMAGAWA, Masaaki MORI, Shumpei YOKOTA, Infliximab therapy for three adolescent patients with refractory Takayasu's arteritis, Japanese Journal of Clinical Immunology, 2010, 33, 6, 317

    CrossRef

  108. 108
    Matthieu Allez, Konstantinos Karmiris, Edouard Louis, Gert Van Assche, Shomron Ben-Horin, Amir Klein, Janneke Van der Woude, Filip Baert, Rami Eliakim, Konstantinos Katsanos, Jørn Brynskov, Flavio Steinwurz, Silvio Danese, Severine Vermeire, Jean-Luc Teillaud, Marc Lémann, Yehuda Chowers, Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects, Journal of Crohn's and Colitis, 2010, 4, 4, 355

    CrossRef

  109. 109
    Denis Mulleman, Delphine Chu Miow Lin, Emilie Ducourau, Patrick Emond, David Ternant, Charlotte Magdelaine-Beuzelin, Jean-Pierre Valat, Gilles Paintaud, Philippe Goupille, Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis, Therapeutic Drug Monitoring, 2010, 1

    CrossRef

  110. 110
    Rochelle Robicheaux Clementine, Justin Lyman, Jerald Zakem, Jyothi Mallepalli, Stephen Lindsey, Robert Quinet, Tumor Necrosis Factor-Alpha Antagonist-Induced Sarcoidosis, JCR: Journal of Clinical Rheumatology, 2010, 16, 6, 274

    CrossRef

  111. 111
    Carina de Lemos Rieper, Pia Galle, Morten Bagge Hansen, Characterization and potential clinical applications of autoantibodies against cytokines, Cytokine & Growth Factor Reviews, 2009, 20, 1, 61

    CrossRef

  112. 112
    Roman Krzysiek, Maxime Breban, Philippe Ravaud, Maria Vittoria Prejean, John Wijdenes, Carine Roy, Yves-Dominique Henry, Carole Barbey, Gérard Trappe, Maxime Dougados, Dominique Emilie, Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study, Arthritis Care & Research, 2009, 61, 5
  113. 113
    Gerrit J Wolbink, Lucien A Aarden, BAC Dijkmans, Dealing with immunogenicity of biologicals: assessment and clinical relevance, Current Opinion in Rheumatology, 2009, 21, 3, 211

    CrossRef

  114. 114
    Pierre Geborek, Identifying predictors of drug effectiveness in observational studies in rheumatoid arthritis: a challenging task, International Journal of Clinical Rheumatology, 2009, 4, 1, 25

    CrossRef

  115. 115
    Charlotte Magdelaine-Beuzelin, Séverine Vermeire, Margaret Goodall, Filip Baert, Maja Noman, Gert Van Assche, Marc Ohresser, Danielle Degenne, Jean-Michel Dugoujon, Roy Jefferis, Paul Rutgeerts, Maire-Paule Lefranc, Hervé Watier, IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab, Pharmacogenetics and Genomics, 2009, 19, 5, 383

    CrossRef

  116. 116
    Andrea Cassinotti, Simon Travis, Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review, Inflammatory Bowel Diseases, 2009, 15, 8
  117. 117
    Laurence J. Egan, Pharmacology and Therapeutics, 2009,

    CrossRef

  118. 118
    Jean Bousquet, Raphael Chiron, Marc Humbert, Biologics in asthma: difficulties and drawbacks, Expert Opinion on Biological Therapy, 2008, 8, 12, 1921

    CrossRef

  119. 119
    Lucien Aarden, Sigrid R Ruuls, Gertjan Wolbink, Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement, Current Opinion in Immunology, 2008, 20, 4, 431

    CrossRef

  120. 120
    J.R. Mekkes, J.D. Bos, Long-term efficacy of a single course of infliximab in hidradenitis suppurativa, British Journal of Dermatology, 2008, 158, 2
  121. 121
    L.L.A. Lecluse, G. Piskin, J.R. Mekkes, J.D. Bos, M.A. De Rie, Review and expert opinion on prevention and treatment of infliximab-related infusion reactions, British Journal of Dermatology, 2008, 159, 3
  122. 122
    Daniel Tracey, Lars Klareskog, Eric H. Sasso, Jochen G. Salfeld, Paul P. Tak, Tumor necrosis factor antagonist mechanisms of action: A comprehensive review, Pharmacology & Therapeutics, 2008, 117, 2, 244

    CrossRef

  123. 123
    Mark A. Ainsworth, Klaus Bendtzen, Jørn Brynskov, Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease, The American Journal of Gastroenterology, 2008, 103, 4, 944

    CrossRef

  124. 124
    Nicolino Ruperto, Daniel J. Lovell, Ruben Cuttica, Nick Wilkinson, Patricia Woo, Graciela Espada, Carine Wouters, Earl D. Silverman, Zsolt Balogh, Michael Henrickson, Maria-Teresa Apaz, Eileen Baildam, Anders Fasth, Valeria Gerloni, Pekka Lahdenne, Anne-Marie Prieur, Angelo Ravelli, Rotraud K. Saurenmann, Maria Luz Gamir, Nico Wulffraat, Laszlo Marodi, Ross E. Petty, Rik Joos, Francesco Zulian, Deborah McCurdy, Barry L. Myones, Kalman Nagy, Peter Reuman, Ilona Szer, Suzanne Travers, Anna Beutler, Greg Keenan, Jason Clark, Sudha Visvanathan, Adedigbo Fasanmade, Aparna Raychaudhuri, Alan Mendelsohn, Alberto Martini, Edward H. Giannini, A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis, Arthritis & Rheumatism, 2007, 56, 9
  125. 125
    James S. Bourdage, Carolyn A. Cook, Daphne L. Farrington, Jana S. Chain, Robert J. Konrad, An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug, Journal of Immunological Methods, 2007, 327, 1-2, 10

    CrossRef

  126. 126
    Gino A Vena, Nicoletta Cassano, Anti-tumor necrosis factor therapies for psoriasis, Expert Review of Dermatology, 2007, 2, 3, 335

    CrossRef

  127. 127
    Claus H Nielsen, Daniel El Fassi, Hans C Hasselbalch, Klaus Bendtzen, Laszlo Hegedüs, B-cell depletion with rituximab in the treatment of autoimmune diseases, Expert Opinion on Biological Therapy, 2007, 7, 7, 1061

    CrossRef

  128. 128
    Kassie A. Haitz, Robert E. Kalb, Infliximab in the treatment of psoriasis in patients previously treated with etanercept, Journal of the American Academy of Dermatology, 2007, 57, 1, 120

    CrossRef

  129. 129
    Aysegul Yucel, Arzu L. Aral, Bilkay Basturk, Resul Karakus, Canan Aybay, Cemalettin Aybay, Investigation of the functional characteristics of antibodies to therapeutic anti-human tumor necrosis factor alpha monoclonal antibody, Immunology Letters, 2007, 111, 2, 84

    CrossRef

  130. 130
    B. Díaz-Ley, G. Guhl, J. Fernández-Herrera, Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 1: Infliximab and Adalimumab, Actas Dermo-Sifiliográficas (English Edition), 2007, 98, 10, 657

    CrossRef

  131. 131
    Daniel J Pearce, Steven R Feldman, Update on infliximab: an intravenous biologic therapy for psoriasis, Expert Review of Dermatology, 2007, 2, 6, 707

    CrossRef

  132. 132
    Ryuji Koike, Tsutomu Takeuchi, Katsumi Eguchi, Nobuyuki Miyasaka, Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis, Modern Rheumatology, 2007, 17, 6, 451

    CrossRef

  133. 133
    Ryuji Koike, Tsutomu Takeuchi, Katsumi Eguchi, Nobuyuki Miyasaka, Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis, Modern Rheumatology, 2007, 17, 6, 451

    CrossRef

  134. 134
    B. Díaz-Ley, G. Guhl, J. Fernández-Herrera, Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab, Actas Dermo-Sifiliográficas, 2007, 98, 10, 657

    CrossRef

  135. 135
    Pia Galle, Lene Jensen, Christina Andersson, Salvatore Cuzzocrea, Rosanna Di Paola, Ferdinando Nicoletti, Morten Svenson, Klaus Bendtzen, Allan R. Thomsen, Morten B. Hansen, Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation, International Immunopharmacology, 2007, 7, 13, 1704

    CrossRef

  136. 136
    Jennifer L. Jones, Are all Anti-TNF Agents the Same?,
  137. 137
    Anthony Meager, Cell-Based Assays for the Detection of Neutralizing Antibodies to Interferon Beta (IFN-β) and Tumor Necrosis Factor Alpha (TNF-α) Inhibitors,
  138. 138
    Klaus Bendtzen, Morten Svenson, Enzyme Immunoassays and Radioimmunoassays for Quantification of Anti-TNF Biopharmaceuticals and Anti-Drug Antibodies,